Source: TripAdvisor

Over the last couple of years it has taken us until the end of July to rollout all of our coverage of AACR and ASCO, since data often co-mingles across the two key conferences… and this year is no exception to the rule.

Here we digest an early allcomers trial and point out some red and green flags to watch out for as we review some of the highlights in terms of what can be learned and what’s missing, but would be useful to know.

The short answer is there is quite a bit to discuss on both fronts…


BSB subscribers can learn more about our latest look at the TIGIT niche – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Posted by